NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

HERAMED LIMITED (HMD)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 

Shareholder links

Our website ranking of HMD: rating 3
(3 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

XCEND PTY LTD
Level 1, 139 Macquarie Street SYDNEY NSW 2000
Tel : 61 2 7208 8033
RegistryWebsite RegistryEmail

Company details

ISIN: AU0000028367
Address: Suite 4, Level 16 55 Clarence Street SYDNEY NSW 2000
Tel:  +61 2 8379 2961

Date first listed: 12/12/2018
Company Secretary: Cameron Jones
Sector: Health Care Equipment & Services 
Activities: Development, manufacture and distribution of fetal heart beat monitors and other pregnancy-related solutions

News & Events

Expand this box to read and print

HeraMED Limited advises that the Annual General Meeting of the Company is intended to be held on Thursday 30 May 2024. Any person wishing to be considered for election as a director must provide their nomination to the Company, which must be received at the Company's registered office no later than 5.00pm (AEST) on Wednesday, 17 April 2024.

10/04/2024

As outlined in ASX announcement titled Supplemental information "“ Voluntary Suspension on 8 April 2024, the Company requests that the suspension remains in place until the Company releases an announcement in relation to the restructure of the business, the financial position of the Company, associated capital requirements and proposed financing to fund ongoing operations of the business. The discussions referred to above are ongoing, and at this stage it is difficult to predict a timetable for their conclusion however the Company is working to finalise the above matters urgently and currently intends to make that announcement by 29 April 2024. Further updates will be provided in due course.

09/04/2024

The company releases supplemental information regarding the suspension of its securities. The Company is actively engaged with third parties to secure additional funding. Successful completion of additional funding is critical to the Company's continued financial viability. In connection with seeking to secure further funding, the Company is reviewing the structure of its business operations and associated capital requirements. In the Company's opinion, continued trading of its securities is likely to materially prejudice its ability to complete the discussions with third partiesto secure additional funding and to resolve the nature and extent of changes to it Director and Management.

08/04/2024

The company releases supplemental information regarding the suspension of its securities. The Company is actively engaged with third parties to secure additional funding. Successful completion of additional funding is critical to the Company's continued financial viability. In connection with seeking to secure further funding, the Company is reviewing the structure of its business operations and associated capital requirements. In the Company's opinion, continued trading of its securities is likely to materially prejudice its ability to complete the discussions with third partiesto secure additional funding and to resolve the nature and extent of changes to it Director and Management.

08/04/2024

The securities of HeraMED Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of HMD, pending the release of an announcement regarding changes in Directors and Management, the restructure of the business, associated capital requirements and proposed financing to fund ongoing operations of the business which is critical to the Company's financial viability.

05/04/2024

The securities of HeraMED Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of HMD, pending the release of an announcement regarding changes in Directors and Management, the restructure of the business, associated capital requirements and proposed financing to fund ongoing operations of the business which is critical to the Company's financial viability.

05/04/2024

The suspension of trading in the securities of HeraMED Limited will be lifted immediately following the release by HMD of an announcement regarding a material contract.

28/02/2024

Broward Health is one of the 10 largest public healthcare systems in the US and includes five hospitals, across more than 50 locations and offices, and a team of over 1,800 nationally recognised doctors; Broward Health has signed a two-year agreement for adoption of the HeraCARE platform, beginning with 700 HeraCARE licenses and 200 bundles of hardware (including HeraBEAT devices), representing the largest deployment in USA to date; Broward Health will pay HeraMED US$99,600 up front for 200 bundles (each bundle to include a HeraBEAT, Blood Pressure Cuff, Bluetooth Scales, and a co-branded Diaper bags). Broward Health will also pay US$100,400 in advance in each of the next two years, for up to 700 active licenses; There is an option for Broward to purchase another 200 bundles for US$99,600 at any point during the two years. And if Broward exercise this option, then the total consideration would be approximately US$400,000 over the two years representing.

28/02/2024

The securities of Heramed Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of HMD, in relation to an announcement to the market regarding a material new contract.

26/02/2024

The suspension of trading in the securities of HeraMED Limited will be lifted immediately following the release by HMD of an announcement regarding an Australian based commercial licence agreement for the rollout of the HeraCARE solution.

21/01/2022

● Joondalup Health Campus (JHC) has entered into a full-scale long-term commercial agreement with medical data and technology company HeraMED to adopt the complete HeraCARE solution as the primary standard of care offered for their audience of expecting mothers. Commercial terms reached under the paid pilot agreement, including the SaaS fees, will extend for 12 months, with both parties exploring extension of the contract for a further three years. The contract value for the first 12 months is expected to be approximately A$220,000. HMD will progressively deliver HeraCARE SaaS licences (including the HeraBEAT smart foetal monitors) to support JHC's services expansion. This is the first major Healthcare group to adopt the comprehensive HeraCARE virtual and remote monitoring solution as part of their innovative care model for pregnant mothers. This agreement validates HeraMED's commercialisation strategy undertaking clinical trials leading to paid pilots and then ultimately full commercial deployment within a leading hospital group. JHC (part of Ramsay Health Care) is one of Western Australia's largest hospitals, a leading medical institution, and a maternity care service provider to an average of 3,000 expectant mothers annually.

21/01/2022

The securities of HeraMed Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of HMD, pending the release of an announcement regarding an Australian based commercial licence agreement for the roll-out of the HeraCARE solution.

20/01/2022

The suspension of trading in the securities of HeraMED Limited will be lifted immediately, following the release by HMD of an announcement regarding finalising a material collaboration agreement.

21/07/2020

The company releases a notice of Proposed issue of Securities - HMD.

21/07/2020

The company is extending its collaboration with Mayo Clinic with a new agreement for the development of its HeraCARE pregnancy management platform that includes an equity investment to support the project.

21/07/2020

The securities of HeraMED Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of HMD, pending the release of an announcement regarding finalising a material collaboration agreement.

20/07/2020

listed entity carried for record purposes only

12/12/2018

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    23/03/2023Ron Weinberger215,000$0.114$24,553
    03/08/2020Ron Weinberger286,000$0.094$26,741

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Anoushka GungadinCEO10/04/2024
    Cameron JonesCFO10/04/2024
    David HintonNon Exec Director23/08/2018
    Timothy ChapmanNon Exec Director11/03/2024
    Ron WeinbergerDirector23/08/2018

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Doron BirgerNon Exec Director07/10/201811/03/2024
    Emily SladeNon Exec Director13/09/202217/01/2024
    David GrobermanManaging Director, CEO27/09/201808/11/2023
    Tal SlonimDirector, COO29/09/201820/04/2023

    Date of first appointment, title may have changed.